This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Covetrus Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Wichtige Informationen
50.8%
Wachstumsrate der Gewinne
50.7%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 20.8% |
| Wachstumsrate der Einnahmen | 6.3% |
| Zukünftige Eigenkapitalrendite | 10.6% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | n/a |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2024 | 5,385 | 100 | 125 | N/A | 4 |
| 12/31/2023 | 5,084 | 52 | 92 | N/A | 5 |
| 12/31/2022 | 4,795 | 10 | 112 | N/A | 5 |
| 6/30/2022 | 4,649 | -13 | 2 | 60 | N/A |
| 3/31/2022 | 4,621 | -40 | 70 | 126 | N/A |
| 12/31/2021 | 4,575 | -54 | 42 | 102 | N/A |
| 9/30/2021 | 4,575 | -56 | 44 | 104 | N/A |
| 6/30/2021 | 4,539 | -90 | -60 | 2 | N/A |
| 3/31/2021 | 4,376 | -13 | 10 | 72 | N/A |
| 12/31/2020 | 4,339 | -26 | -5 | 53 | N/A |
| 9/30/2020 | 4,225 | -19 | 31 | 80 | N/A |
| 6/30/2020 | 4,117 | -940 | 112 | 154 | N/A |
| 3/31/2020 | 4,100 | -996 | 18 | 58 | N/A |
| 12/31/2019 | 3,976 | -980 | 64 | 103 | N/A |
| 9/30/2019 | 3,871 | -948 | 93 | 130 | N/A |
| 6/30/2019 | 3,776 | 27 | 83 | 113 | N/A |
| 3/31/2019 | 3,772 | 65 | 131 | 157 | N/A |
| 12/29/2018 | 3,778 | 101 | 136 | 158 | N/A |
| 9/30/2018 | 3,791 | 69 | 74 | 94 | N/A |
| 6/30/2018 | 3,776 | 74 | 103 | 127 | N/A |
| 3/31/2018 | 3,649 | 67 | 42 | 64 | N/A |
| 12/30/2017 | 3,580 | 64 | 87 | 108 | N/A |
| 12/31/2016 | 3,353 | 70 | 92 | 105 | N/A |
| 12/26/2015 | 2,978 | 60 | N/A | 96 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 2NJ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.03%).
Ertrag vs. Markt: 2NJ is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hohe Wachstumserträge: 2NJ is expected to become profitable in the next 3 years.
Einnahmen vs. Markt: 2NJ's revenue (6.3% per year) is forecast to grow faster than the German market (3.9% per year).
Hohe Wachstumseinnahmen: 2NJ's revenue (6.3% per year) is forecast to grow slower than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 2NJ's Return on Equity is forecast to be low in 3 years time (10.6%).